BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26980473)

  • 1. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.
    Huang J; Fan Q; Lu P; Ying J; Ma C; Liu W; Liu Y; Tan F; Sun Y
    J Thorac Oncol; 2016 Jun; 11(6):910-7. PubMed ID: 26980473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma.
    Wang X; Niu H; Fan Q; Lu P; Ma C; Liu W; Liu Y; Li W; Hu S; Ling Y; Guo L; Ying J; Huang J
    Oncotarget; 2016 Apr; 7(17):24744-51. PubMed ID: 27013591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial.
    Luo H; Jiang W; Ma L; Chen P; Fang M; Ding L; Hua Y; Du D; Jing Z; Xie R; Song Y; Wang J; Zhou R; Tian Z; Wu S
    JAMA Netw Open; 2020 Oct; 3(10):e2019440. PubMed ID: 33026449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.
    Xu J; Liu X; Yang S; Zhang X; Shi Y
    Asia Pac J Clin Oncol; 2017 Dec; 13(6):379-384. PubMed ID: 28276163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
    Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
    Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of icotinib in advanced lung squamous cell carcinoma.
    Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
    Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
    Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
    Wang HP; Zhang L; Wang YX; Tan FL; Xia Y; Ren GJ; Hu P; Jiang J; Wang MZ; Xiao Y
    Chin Med J (Engl); 2011 Jul; 124(13):1933. PubMed ID: 22088449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma.
    Wang H; Jiang D; Song Q; Xu C; Shi Y; Li X; Huang J; Xu Y; Sujie A; Zeng H; Zhong Y; Tan L; Hou Y
    Tumour Biol; 2016 Jul; 37(7):9771-9. PubMed ID: 26810066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
    Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
    Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
    Liu R; Liu L; Zhao C; Bai Y; Zheng Y; Zhang S; Li N; Yang J; Fan Q; Wang X; Zeng S; Zhang Y; Zhang W; Zhuang Y; Kang N; Jiang Y; Sun H; Xu J
    BMC Gastroenterol; 2021 Oct; 21(1):398. PubMed ID: 34688250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
    Liu J; Wu L; Wu G; Hu X; Zhou H; Chen J; Zhu M; Xu W; Tan F; Ding L; Wang Y; Shentu J
    Oncologist; 2016 Nov; 21(11):1294-1295d. PubMed ID: 27789778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of the telomerase RNA component gene as a new genetic marker for disease progression and prognosis in esophageal squamous cell carcinoma.
    Wang JD; Ma J; Wang FY; Peng LB; Wang X; Shi SS; Ma HH; Lu ZF; Lu GM; Zhou XJ
    Dis Esophagus; 2013; 26(7):737-45. PubMed ID: 23317107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.
    Hanawa M; Suzuki S; Dobashi Y; Yamane T; Kono K; Enomoto N; Ooi A
    Int J Cancer; 2006 Mar; 118(5):1173-80. PubMed ID: 16161046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
    Fan Y; Huang Z; Fang L; Miao L; Gong L; Yu H; Yang H; Lei T; Mao W
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):517-23. PubMed ID: 26148750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.